Welcome to our dedicated page for Crescita Therape news (Ticker: CRRTF), a resource for investors and traders seeking the latest updates and insights on Crescita Therape stock.
Crescita Therapeutics Inc. reports developments as a Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The company commercializes branded non-prescription skincare products, sells other brands under exclusive distribution agreements, licenses intellectual property related to Pliaglis®, and provides contract manufacturing and product development services.
Company news commonly covers operating and financial results across its Commercial Skincare, Licensing and Royalties, and Manufacturing and Services segments. Updates also include material agreements, licensing rights, product and regulatory disclosures, acquisitions of dermatology or skincare assets, normal course share repurchases, and shareholder voting matters such as board elections and shareholder-rights-plan approvals.
Crescita Therapeutics (OTC: CRRTF, TSX: CTX) obtained a final court order approving its plan of arrangement with ClinActiv Holdings and its subsidiary. The purchaser will acquire all Crescita common shares for all-cash consideration at a target price of $0.80 per share, adjustable based on net working capital with a minimum of $0.75 per share. Closing is expected in Q2 2026, after remaining conditions are met. Following completion, Crescita shares are expected to be delisted from the TSX and the company plans to cease being a reporting issuer in Canada.
Crescita Therapeutics (OTC: CRRTF, TSX: CTX) Shareholders approved a plan of arrangement for acquisition by ClinActiv Holdings’ subsidiary for all-cash consideration.
The target purchase price is $0.80 per share, adjustable based on net working capital, with a minimum of $0.75. The Arrangement received 99.58% overall and 99.53% minority approval and is expected to close in Q2 2026, subject to court approval and customary conditions, after which Crescita expects TSX delisting and to cease being a reporting issuer.
Crescita Therapeutics (OTC:CRRTF, TSX:CTX) reported Q1 2026 revenue of $5,637k, up from $3,537k, with gross profit of $2,644k and gross margin of 46.9%. Operating expenses rose to $3,849k, driving a net loss of $1,160k, while Adjusted EBITDA turned positive at $238k.
Crescita agreed to be acquired by ClinActiv for $0.80 per share in cash, subject to working capital adjustments and a $0.75 minimum, a 74% premium to the prior five-day VWAP. Closing is targeted for Q2 2026, after shareholder and court approvals, with TSX delisting expected.
Crescita Therapeutics (OTC: CRRTF, TSX: CTX) filed and mailed the management information circular for a special meeting on May 14, 2026 to vote on a court‑supervised plan of arrangement under which ClinActiv Purchaser will acquire all shares for all‑cash consideration.
The target purchase price is $0.80 per share (adjusted for closing net working capital, floor $0.75). The Board unanimously recommends the Arrangement (CEO abstained). An interim court order dated April 10, 2026 authorizes proceeding; closing is expected in Q2 2026, with TSX delisting and cessation of Canadian reporting upon closing.
Crescita Therapeutics (OTC: CRRTF) reported Q4-2025 revenue of $5.96M and full-year 2025 revenue of $21.12M. Gross margin improved to 52.6% (FY2025) and Adjusted EBITDA turned positive at $0.62M. Net loss narrowed to $0.09M for FY2025. Subsequent to year-end, Crescita agreed to be acquired by ClinActiv at $0.80/share (target), representing an approximate 74% premium; closing is subject to shareholder and court approvals.
Other items: LPC asset purchase for $775k (estimated fair value $1.383M), a five-year exclusive supply agreement, lease renewal to 2031, and a €575k termination payment received for Pliaglis rights.
Crescita (OTC: CRRTF) entered a definitive agreement to be acquired by ClinActiv in an all-cash arrangement at a target price of $0.80 per share (minimum $0.75), representing ~74% premium to the five-day VWAP as of March 13, 2026. Closing is expected in Q2 2026 subject to shareholder and court approvals.
The deal includes voting support representing ~33% of shares, a C$2.0M termination fee, a US$1.5M reverse termination fee, a post-closing reorganization of certain assets, and anticipated TSX delisting and cessation of public reporting upon close.
Crescita (OTC: CRRTF) reported Q3-2025 results for the quarter ended September 30, 2025. Revenue was $5,393K, up $1,799K vs Q3-2024; gross profit was $2,855K (52.9% margin). The company recorded net income $753K versus a net loss of $(1,036)K in Q3-2024 and Adjusted EBITDA $262K versus $(681)K.
Key corporate actions: acquisition of select assets from Laboratoire Provence-Canada for $775K cash (fair value $1,383K) including the Bacti Control brand, a newly signed exclusive 5-year supply agreement with a former LPC customer, and share repurchases under an NCIB (436,692 shares, $223K YTD). Cash ended at $8,308K.
Crescita Therapeutics (OTC:CRRTF) reported strong Q2 2025 financial results, with revenue increasing to $6.23 million, up from $4.09 million in Q2 2024. The company achieved a net income of $798,000 compared to a net loss of $926,000 in the prior year period. Key highlights include a significant improvement in Adjusted EBITDA to $964,000 from -$686,000.
The quarter featured a mutual termination agreement with Croma Pharma for Pliaglis® rights in certain European territories, contributing $902,000 to revenue. The company's Commercial Skincare segment showed growth, while Manufacturing segment benefited from new customer orders. Crescita maintained a strong cash position of $8.18 million and continued its share repurchase program, buying back 107,004 shares during Q2.